The paper evaluates gefurulimab, described as the first nanobody therapeutic, for use in myasthenia gravis (MG) therapy — assessing its efficacy and role in treatment.
Gefurulimab is presented as the first effective nanobody in MG therapy, though specific quantitative outcome data (e.g., responder rates, scale scores) are not available from the provided source text.
The full study details, including sample size, comparator arms, follow-up duration, and primary endpoint data, are not available from the provided abstract/metadata alone.
Gefurulimab represents a novel nanobody-based therapeutic class for myasthenia gravis; clinicians should monitor emerging trial data for efficacy and safety specifics before adopting it into practice.
Explore related topics
